Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

118.97 +3.17 (+2.74%)
Streaming Delayed Price Updated: 11:10 AM EDT, Sep 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
72 73 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis. 
Via Benzinga
A Look Into Merck & Co's Debt
Via Benzinga
Expert Ratings for Merck & Co
Via Benzinga
Peering Into Merck & Co's Recent Short Interest
Via Benzinga
Why OPKO Health Shares Jumped on Wednesday
A major pharma name is showing interest in one of the company's vaccine prospects. 
Via The Motley Fool
Stock Market Tumbles Amid SVB Financial Collapse, 'Faster' Powell: Weekly Review
The major indexes suffered serious losses this past week. 
Via Investor's Business Daily
Merck's Keytuda+Chemo Combo Improves Overall Survival In Patients With Advanced Mesothelioma
Merck & Co Inc (NYSE: MRK) announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial of Keytruda plus chemotherapy combo met its primary endpoint in unresectable advanced or metastatic malignant... 
Via Benzinga
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to... 
Via Benzinga
Dividend Stocks Alert: 10 Top Holdings From the SCHD ETF
Dividend funds like the SCHD ETF are gaining traction ahead of its March 27 dividend payment. What are the top 10 holdings in the ETF? 
Via InvestorPlace
Merck Highlights Promising Data From Two Candidates In Heart Diseases
Via Benzinga
Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings
Via Benzinga
Here's How Much $1000 Invested In Merck & Co 5 Years Ago Would Be Worth Today
Via Benzinga
OPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck
Via Benzinga
2 Top Healthcare Stocks to Buy Right Now
Most people eventually need the healthcare goods/services that these companies provide. 
Via The Motley Fool
Beat the Dow Jones With This Unstoppable Dividend Stock
Merck had a strong year and has the portfolio and pipeline to increase its dividend. 
Via The Motley Fool
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success
Via Benzinga
Keytruda Who? Merck Nears Breakout On $10 Billion Sales Potential For Heart Drugs
The heart segment is becoming more important as Keytruda near patent expiration. 
Via Investor's Business Daily
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at... 
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Secrets Of Great Long-Term Stock Investors
What can the rest of us learn from Warren Buffett's long-term stock buys? Here are 5 stock ideas for long-term investors. 
Via Talk Markets
Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million
Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Allist Pharma in a $188 million deal. Also, Chipscreen Bio acquired greater China rights to a... 
Via Talk Markets
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytuda Regime Study In Lung Cancer Patients
Via Benzinga
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Analyst Cautions Investors On Overreacting To 'Early-Stage' Pfizer/Seagen Discussions
Via Benzinga
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
The potential deal follows rumors last year that Merck could buy Seagen. 
Via Investor's Business Daily
Seagen Stock Soars On Pfizer Takeover Talks: What's Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday following reports indicating pharmaceutical giant Pfizer Inc (NYSE: 
Via Benzinga
Pfizer In Early Talks To Buy Cancer-Focused Seagen: WSJ
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
72 73 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.